GlassScriptPhysician profile
Rohini Samudralwar
NPI 1720421373
$110,570.43
in general payments reported to CMS, 2019-2025
16 companies · $4,483 in 2025
The $4,483 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $42K · 2021: $14K · 2022: $756 · 2023: $4,258 · 2024: $16K · 2025: $4,483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $20K · Food and Beverage: $3,588 · Travel and Lodging: $881.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $20,237.50 |
| Food and Beverage | $3,588.21 |
| Travel and Lodging | $881.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $63,872.23 | 2019-2024 | Vumerity, Tecfidera |
| Emd Serono, INC. | $23,527.15 | 2019-2025 | Mavenclad |
| Tg Therapeutics, INC. | $8,376.50 | 2024-2025 | |
| Amgen INC. | $5,932.25 | 2019-2024 | Uplizna |
| Genentech USA, INC. | $5,470.57 | 2019-2025 | Ocrevus |
| Alexion Pharmaceuticals, INC. | $1,728.96 | 2020-2024 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $776.35 | 2019-2024 | |
| Genzyme Corporation | $421.18 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $123.61 | 2022 | |
| Celgene Corporation | $118.42 | 2019 | |
| Abbvie INC. | $84.21 | 2021-2023 | Qulipta |
| Boston Scientific Corporation | $72.44 | 2022 | |
| Banner Life Sciences, LLC | $23.28 | 2022 | |
| Amneal Pharmaceuticals LLC | $15.52 | 2021 | |
| Sanofi-Aventis U.S. LLC | $15.32 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tanabe Pharma America, INC. | $12.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohini Samudralwar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.